CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 45 enrolled
Drug / intervention
Digoxin +2 moredrug
Likely dose
Digoxin 3 mcg/Kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03559868
NCT03559868Phase 1Completed
CompareCT.gov

Inhibition of Sterile Inflammation by Digoxin

Yale University·interventional·Posted Jun 18, 2018·Updated Jul 12, 2024

In Brief

A Phase 1 clinical trial evaluating Digoxin and Placebo for Inflammatory Response. Completed, enrolled 45 participants across 1 site.

Detailed Summary

To investigate the effect of digoxin on pyruvate kinase isoform 2 (PKM2) binding to pro-inflammatory loci and innate immune inflammatory responses in the peripheral blood in healthy subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammatory Response
CountriesUnited States
CollaboratorsNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedJun 18, 2018
Enrollment StartMar 1, 2021
Primary CompletionMay 5, 2023
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 8.0 years ago

Interventions

Digoxindrug

Participants will receive 3 mcg/Kg/day doses of oral digoxin

Placeboother

Oral placebo

Digoxindrug

Participants will receive 0.15 mcg/Kg/day doses of oral digoxin